Abstract 40P
Background
Recent evidence suggests that breast cancer may have population-specific characteristics, including differences in the tumour immune microenvironment (TME). Immune cell markers in the TME, particularly CD8, may have utility as predictive and prognostic biomarkers, but there is conflicting evidence from previous studies. The aim of this study was to determine the prognostic utility of immune cell immunohistochemistry markers in tumor samples from a cohort of breast cancer patients from Malaysia.
Methods
We obtained digitized whole slide images of breast tumour tissue samples stained for CD3, CD4, CD8, and PD-L1 markers for 576 breast cancer patients from Subang Jaya Medical Centre, a Malaysian private hospital. These patients were included in the Malaysian Breast Cancer (MyBrCa) study cohort, and thus multi-omics data were also available for analysis for each patient. We also obtained overall survival data from the Malaysian national registry for this group of patients, with a median follow-up time of 68 months.
Results
We compared the intra-tumoral scores for each marker to overall survival data and found that the scores for CD3, CD4, and CD8, but not PD-L1, were positively associated with overall survival, particularly for patients with triple-negative breast cancer (TNBC). Additionally, the CD3, CD4, and CD8 scores were not associated with tumour mutational burden (TMB) or neoantigen load and had a negative correlation with copy number aberrations.
Conclusions
Our results suggest that intra-tumoral markers for T-cells are indicative of good prognosis in Asian breast cancer. Our results also suggest that the TME in Asian breast cancer may be shaped by non-canonical pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Cancer Research Malaysia, Yayasan PETRONAS, Yayasan Sime Darby, Scientex Foundation, Estee Lauder Companies, Vistage Malaysia, Newton-Ungku Omar Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract